Information:
Error:
ID
27842
Description
Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B; ODM derived from: https://clinicaltrials.gov/show/NCT00781105
Link
https://clinicaltrials.gov/show/NCT00781105
Keywords
Versions (1)
- 11/30/17 11/30/17 -
Copyright Holder
See clinicaltrials.gov
Uploaded on
November 30, 2017
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Chronic Hepatitis B NCT00781105
Eligibility Chronic Hepatitis B NCT00781105
- StudyEvent: Eligibility
Similar models
Eligibility Chronic Hepatitis B NCT00781105
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Age
Item
male or female 16 to 65 year of age
boolean
C0001779 (UMLS CUI [1])
Hepatitis B, Chronic | Hepatitis B Surface Antigens Detectable | Hepatitis B DNA Measurement
Item
documented chb defined by detectable serum hbsag and serum hbv dna level
boolean
C0524909 (UMLS CUI [1])
C0019168 (UMLS CUI [2,1])
C3830527 (UMLS CUI [2,2])
C3641250 (UMLS CUI [3])
C0019168 (UMLS CUI [2,1])
C3830527 (UMLS CUI [2,2])
C3641250 (UMLS CUI [3])
Protocol Compliance
Item
willing and able to comply with the study drug regimen
boolean
C0525058 (UMLS CUI [1])
Informed Consent
Item
written informed consent before any assessment
boolean
C0021430 (UMLS CUI [1])
Hepatic decompensation | Sign or Symptom Hepatic decompensation
Item
patient has a history of/or clinical signs/symptoms of hepatic decompensation
boolean
C1394798 (UMLS CUI [1])
C3540840 (UMLS CUI [2,1])
C1394798 (UMLS CUI [2,2])
C3540840 (UMLS CUI [2,1])
C1394798 (UMLS CUI [2,2])
Liver carcinoma | Liver carcinoma Suggestive of
Item
patient has a history of hcc or findings suggestive of possible hcc
boolean
C2239176 (UMLS CUI [1])
C2239176 (UMLS CUI [2,1])
C0332299 (UMLS CUI [2,2])
C2239176 (UMLS CUI [2,1])
C0332299 (UMLS CUI [2,2])
Nucleosides Pharmaceutical Preparations | Nucleotides Pharmaceutical Preparations | Nucleosides Investigational New Drugs | Nucleotides Investigational New Drugs
Item
patient has received treatment of nucleoside or nucleotide drugs whether approved or investigational at any time
boolean
C0028621 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C0028630 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C0028621 (UMLS CUI [3,1])
C0013230 (UMLS CUI [3,2])
C0028630 (UMLS CUI [4,1])
C0013230 (UMLS CUI [4,2])
C0013227 (UMLS CUI [1,2])
C0028630 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C0028621 (UMLS CUI [3,1])
C0013230 (UMLS CUI [3,2])
C0028630 (UMLS CUI [4,1])
C0013230 (UMLS CUI [4,2])
Hypersensitivity Investigational New Drugs | Hypersensitivity telbivudine | Hypersensitivity Investigational New Drugs Clinical Class Similar
Item
history of hypersensitivity to any of the drugs (telbivudine) or to drugs of similar clinical classes
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1453933 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0013230 (UMLS CUI [3,2])
C1314971 (UMLS CUI [3,3])
C2348205 (UMLS CUI [3,4])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1453933 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0013230 (UMLS CUI [3,2])
C1314971 (UMLS CUI [3,3])
C2348205 (UMLS CUI [3,4])
Interferons | Immunomodulation
Item
patient has received ifn or other immunomodulatory treatment with 12 months before screening
boolean
C0021747 (UMLS CUI [1])
C1963758 (UMLS CUI [2])
C1963758 (UMLS CUI [2])
Nucleoside Reverse Transcriptase Inhibitor
Item
previous treatment history with nrtis
boolean
C3537103 (UMLS CUI [1])
Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
C2348563 (UMLS CUI [1,2])